Bone Biologics Corp Stock Analysis

Bone Stock Analysis Notes

The company has price-to-book (P/B) ratio of 0.51. Some equities with similar Price to Book (P/B) outperform the market in the long run. Bone Biologics Corp recorded a loss per share of 34.01. The entity last dividend was issued on the 24th of July 2018. The firm had 1:8 split on the 20th of December 2023. Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company was founded in 2004 and is headquartered in Burlington, Massachusetts. Bone Biologics operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 2 people. For more info on Bone Biologics Corp please contact Jeffrey Frelick at 781 552 4452 or go to https://www.bonebiologics.com.

Bone Biologics Corp Investment Alerts

Bone Biologics Corp Upcoming and Recent Events

Bone Largest EPS Surprises

View All Earnings Estimates

Bone Stock Institutional Investors

Note, although Bone Biologics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Bone Market Capitalization

The company currently falls under 'Nano-Cap' category with a current market capitalization of 1.63 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Bone Biologics's market, we take the total number of its shares issued and multiply it by Bone Biologics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.

Bone Profitablity

Management Efficiency

Bone Biologics Corp has return on total asset (ROA) of (0.9634) % which means that it has lost $0.9634 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.0215) %, meaning that it created substantial loss on money invested by shareholders. Bone Biologics' management efficiency ratios could be used to measure how well Bone Biologics manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -2.51. The Bone Biologics' current Return On Capital Employed is estimated to increase to -3.08. At this time, Bone Biologics' Other Assets are most likely to increase significantly in the upcoming years.

Technical Drivers

As of the 5th of May, Bone Biologics shows the Mean Deviation of 5.07, standard deviation of 7.66, and Risk Adjusted Performance of (0.05). Bone Biologics Corp technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to break down and interpolate thirteen technical drivers for Bone Biologics Corp, which can be compared to its peers. Please confirm Bone Biologics Corp variance, maximum drawdown, as well as the relationship between the Maximum Drawdown and skewness to decide if Bone Biologics Corp is priced correctly, providing market reflects its regular price of 1.85 per share. Please also double-check Bone Biologics Corp jensen alpha, which is currently at (0.87) to validate the company can sustain itself at a future point.

Bone Biologics Corp Price Movement Analysis

Bone Biologics Corp Insider Trading Activities

Bone Biologics Predictive Daily Indicators

Bone Biologics Forecast Models

Bone Biologics' time-series forecasting models are one of many Bone Biologics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Bone Biologics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how Bone Biologics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Bone shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Bone Biologics. By using and applying Bone Stock analysis, traders can create a robust methodology for identifying Bone entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Bone analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Bone analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Bone Biologics Corp stock analysis indicators help investors evaluate how Bone Biologics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Bone Biologics shares will generate the highest return on investment. By understating and applying Bone Biologics stock analysis, traders can identify Bone Biologics position entry and exit signals to maximize returns.

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bone Biologics Corp. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..

When running Bone Biologics' price analysis, check to measure Bone Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bone Biologics is operating at the current time. Most of Bone Biologics' value examination focuses on studying past and present price action to predict the probability of Bone Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bone Biologics' price. Additionally, you may evaluate how the addition of Bone Biologics to your portfolios can decrease your overall portfolio volatility.

Is Bone Biologics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bone Biologics. If investors know Bone will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bone Biologics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

The market value of Bone Biologics Corp is measured differently than its book value, which is the value of Bone that is recorded on the company's balance sheet. Investors also form their own opinion of Bone Biologics' value that differs from its market value or its book value, called intrinsic value, which is Bone Biologics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bone Biologics' market value can be influenced by many factors that don't directly affect Bone Biologics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Bone Biologics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Bone Biologics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bone Biologics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.